Habitu
Interactive Patient Communication Platform for Clinical Trials
Company Overview
Snapshot
Founded in November 2018 by Yoav Grinstein and Yaniv Zilberman, Habitu operated with 1–10 employees. The company was acquired by RxE2 in January 2021.
Business overview
Habitu developed an interactive communication platform designed to enhance patient engagement and personalization within clinical trials and decentralized healthcare environments, such as home hospitalization. The platform facilitates a continuous flow of information between patients, their care circles, and medical teams, providing self-treatment recommendations and managing patient commitment. It leverages AI to predict treatment dropout, generate alerts, and offer actionable insights to clinical staff, serving the digital healthcare and life sciences sectors, particularly pharmaceuticals and patient care providers.
Strategic signal
In January 2021, Habitu was acquired by RxE2, a move that integrated Habitu's AI-driven patient data analysis engine into RxE2's pharmacist-led clinical trial platform. This acquisition aimed to enhance RxE2's services by improving patient outcomes and making decentralized clinical trials more accessible and cost-effective, signaling a strategic consolidation in the digital health and clinical trial management space.
Log in to access full profile ›Company Intelligence Q&A
- What was the most significant corporate event for Habitu?
- Habitu was acquired by RxE2 in January 2021. This acquisition aimed to form an AI-driven, pharmacist-led clinical trial platform by integrating Habitu's technology.
- When was Habitu founded and by whom?
- Habitu was founded in November 2018 by co-founders Yoav Grinstein and Yaniv Zilberman.
- What type of technology does Habitu develop?
- Habitu develops an interactive communication platform that uses artificial intelligence to inform, engage, track, and personalize the patient experience in clinical trials and decentralized healthcare settings.
- Which investor participated in Habitu's funding round?
- In April 2020, t-syte led a funding round for Habitu to help the company grow and prepare for a larger seed round.
- What was the strategic impact of the acquisition by RxE2?
- The acquisition by RxE2 in January 2021 was intended to enhance RxE2's pharmacist-led trial services by leveraging Habitu's AI-powered engine for analyzing patient data, thereby improving patient outcomes and decision-making for medical teams.